CRISPR Therapeutics AG (CRSP): Market Cap to Earnings and Growth Ratio

Brandmark of CRISPR (CRSP)

CRISPR Therapeutics AG (CRSP) margins are bolstered by the launch of Casgevy therapy and advancements in oncology. This PEG chart clearly illustrates the valuation dynamics relative to growth rates, where 0.00 serves as the parameter's baseline value. High barriers to entry due to costly trials and patent protection ensure the stability of the business, which relies on a team of top-tier biochemists and geneticists.

CRSP: CRISPR Therapeutics Inc Price/Earnings to Growth Multiple 07/04/2022 - 11/17/2026

Analytical breakdowns for CRISPR Therapeutics (CRSP)

- price and consensus price forecast:
General company analysis:CRSP - CRISPR
Brand item of crisprtx.com

Amidst fierce competition in the genome editing sector, where patents are rendered obsolete by new discoveries, correlating the P/E ratio with growth expectations allows for an assessment of the asset's market value through the lens of profit dynamics. A value below one indicates that CRISPR Therapeutics AG (CRSP) is undervalued relative to its expansion rates, creating a fundamental safety buffer against volatility in the biotechnology sector.

Competitors of CRISPR Therapeutics AG

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|WGS: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - PEG Multiple|SRPT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Twist Bioscience Corp (TWST)|Price/Earnings to Growth Multiple 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio STOK|BLFS - Price/Earnings to Growth Ratio|Wave Life Sciences (WVE) - Price/Earnings to Growth Multiple|MAZE: PEG Multiple|Sionna Therapeutics, Inc. (SION) - PEG Multiple|Price/Earnings to Growth Ratio Prime Medicine, Inc.|TSHA (Taysha) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple QURE (uniQure Pharma)|Growth-Adjusted Market Cap to Net Income meiragtx.com|Price/Earnings to Growth Ratio REGENXBIO RGNX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income